ByteDance Expands Into AI Drug Discovery With Anew Labs

ByteDance, the parent company of TikTok, has expanded its artificial intelligence capabilities into the pharmaceutical sector through Anew Labs, a specialized drug-discovery unit that has begun presenting AI-designed therapies at international scientific conferences.

The unit, also referred to as Anew Therapeutics or ByteDance AI Drug Discovery, operates across a global network with offices in Shanghai, Singapore, and San Jose, California.

According to company information, Anew Therapeutics serves as the operational arm for ByteDance’s AI drug discovery initiatives. The organization focuses on utilizing generative AI and molecular models to develop oral small-molecule therapeutics. These efforts specifically target antibody-validated, protein-protein interaction (PPI) targets within the field of immunology.

Scientific Strategy and Pipeline

The technical approach employed by Anew Labs involves the use of molecular generative models to explore chemical space, paired with in silico evaluation models. These tools are used for the iterative optimization of drug-like properties and potency.

The company recently showcased its first AI-pharma pipeline at the American Association of Immunologists (AAI) Annual Meeting. The presented research focuses on a pan-spectrum small molecule designed to tackle IL-17, a cytokine involved in various inflammatory and autoimmune diseases.

By targeting protein-protein interactions, Anew Labs aims to create breakthrough therapeutics for immunological diseases that have previously been considered unreachable by conventional drug discovery methods.

Organizational Structure and Leadership

The unit’s official website identifies 36 core members contributing to the project. To guide its scientific direction, ByteDance has established a scientific advisory board featuring prominent industry figures.

Among the noted advisors is Liu Yongjun, the former president of Innovent Biologics, a leading biopharmaceutical company in China.

The integration of a high-profile advisory board and a distributed global team suggests a strategy to bridge the gap between big-tech computational power and traditional pharmaceutical expertise.

The move marks a significant diversification for ByteDance, shifting its AI applications from content recommendation and large language models into high-stakes biological research and healthcare development.